Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
FDC ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
FDC Mar-23 |
ACTAVIS Dec-18 |
FDC/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 318 | 16,126 | - | |
Low | Rs | 229 | 10,818 | - | |
Sales per share (Unadj.) | Rs | 107.5 | 3,955.8 | - | |
Earnings per share (Unadj.) | Rs | 11.7 | -1,274.2 | - | |
Cash flow per share (Unadj.) | Rs | 14.0 | 416.9 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 119.5 | 16,315.7 | - | |
Shares outstanding (eoy) | m | 165.91 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.5 | 3.4 | 74.7% | |
Avg P/E ratio | x | 23.4 | -10.6 | -221.4% | |
P/CF ratio (eoy) | x | 19.5 | 32.3 | 60.3% | |
Price / Book Value ratio | x | 2.3 | 0.8 | 277.2% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 45,368 | 4,480,758 | 1.0% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 3,909 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,851.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,076.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 17,838 | 1,315,689 | 1.4% | |
Other income | Rs m | 512 | 25,160 | 2.0% | |
Total revenues | Rs m | 18,350 | 1,340,849 | 1.4% | |
Gross profit | Rs m | 2,496 | 34,478 | 7.2% | |
Depreciation | Rs m | 389 | 562,428 | 0.1% | |
Interest | Rs m | 41 | 75,923 | 0.1% | |
Profit before tax | Rs m | 2,578 | -578,713 | -0.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,595 | 0.0% | |
Tax | Rs m | 640 | -7,334 | -8.7% | |
Profit after tax | Rs m | 1,938 | -423,784 | -0.5% | |
Gross profit margin | % | 14.0 | 2.6 | 534.0% | |
Effective tax rate | % | 24.8 | 1.3 | 1,958.2% | |
Net profit margin | % | 10.9 | -32.2 | -33.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 14,431 | 539,627 | 2.7% | |
Current liabilities | Rs m | 7,296 | 477,372 | 1.5% | |
Net working cap to sales | % | 40.0 | 4.7 | 845.4% | |
Current ratio | x | 2.0 | 1.1 | 175.0% | |
Inventory Days | Days | 265 | 20 | 1,352.8% | |
Debtors Days | Days | 251 | 66 | 378.5% | |
Net fixed assets | Rs m | 17,347 | 148,929 | 11.6% | |
Share capital | Rs m | 166 | 0 | - | |
Net worth | Rs m | 19,820 | 5,426,601 | 0.4% | |
Long term debt | Rs m | 6 | 1,910,903 | 0.0% | |
Total assets | Rs m | 31,796 | 8,483,012 | 0.4% | |
Interest coverage | x | 64.1 | -6.6 | -967.6% | |
Debt to equity ratio | x | 0 | 0.4 | 0.1% | |
Sales to assets ratio | x | 0.6 | 0.2 | 361.7% | |
Return on assets | % | 6.2 | -4.1 | -151.8% | |
Return on equity | % | 9.8 | -7.8 | -125.2% | |
Return on capital | % | 13.2 | -4.8 | -272.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,549 | 470,046 | 0.3% | |
From Investments | Rs m | 111 | 258,229 | 0.0% | |
From Financial Activity | Rs m | -1,800 | -806,740 | 0.2% | |
Net Cashflow | Rs m | -138 | -78,073 | 0.2% |
Compare FDC With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare FDC With: GUJ.INJ(KER) BIOCON ZENITH DRUGS LTD. CORAL LAB. KABRA DRUGS
Asian shares rose cautiously on Friday as markets sobered up to the idea that U.S. rate cuts were most likely some time away.